Skip to main content

DRDO's 2-DG Gets DCGI Approval | INMAS develops anti-covid therapeutic application of 2-deoxy-D-glucose drug

Image
By

 DRDO's 2-DG Gets DCGI Approval | INMAS Develops Anti-Covid Therapeutic Application of 2-Deoxy-D-Glucose Drug


DRDO's anti-Covid drug 2-DG

The anti-COVID-19 therapeutic has been developed by DRDO scientists at the Institute of Nuclear Medicine and Allied Sciences (INMAS).

The Drugs Controller General of India (DCGI), a body responsible for approval of licences of drugs in India, has approved the anti-COVID-19 therapeutic developed by Defence Ministry's  Defence Research and Development Organisation (DRDO). The drug, which received the emergency use authorisation on May 1, is called 2-deoxy-D-glucose (2-DG). According to a press release by the Defence Ministry, clinical trials of 2-DG have demonstrated that it helps in faster recovery of patients severely ill with the COVID-19 disease. The drug helps in faster recovery of hospitalised patients by reducing their dependency on oxygen, which can come in handy in these trying times when the country is suffering from an acute shortage of oxygen concentrators. 

Know everything about DRDO's 2-DG drug

The anti-COVID-19 therapeutic has been developed by DRDO scientists at the Institute of Nuclear Medicine and Allied Sciences (INMAS). The drug has been developed in collaboration between DRDO and Dr Reddy’s Laboratories (DRL) in Hyderabad. The drug was ready for clinical trials in April last year after DRDO and INMAS scientists conducted experiments inside the lab and found 2-DG to be safe and effective against the SARS-CoV-2 virus.

Based on the results from the lab experiment, DCGI permitted DRDO to conduct Phase-II clinical trials of the drug. The trials showed 2-DG was effective against the COVID-19 virus and demonstrated signs of recovery in patients. Following the successful Phase-II trials between May and October 2020, the drug was tested again in Phase-IIa and Phase-IIb trials, which were conducted at six and 11 hospitals respectively. Overall the Phase-II trials were conducted on 110 patients. 

The DRDO received approval to conduct Phase-III trials of the drug by DCGI in November 2020. The Phase-II trials were conducted between December 2020-March 2021 at 27 hospitals across India, including in Delhi, Uttar Pradesh, West Bengal, Maharashtra, Gujarat, Tamil Nadu, Telangana, Karnataka, etc. The Phase-III trials were conducted on 220 patients. The results showed faster recovery in patients who took the drug as compared to those who followed just the Standard of Care (SoC). The use of oxygen in patients who took 2-DG declined significantly. 

How to take the drug?

2-DG comes in powder form, which the infected patients can take orally by mixing up the drug in water. The drug, which is akin to a glucose mix, is easy to manufacture and store, which makes it critical at a time when many people are dying because of the lack of oxygen infrastructure for supply and transportation in India. 



New Source : https://www.republicworld.com/india-news/general-news/drdos-2-dg-gets-dcgi-approval-heres-all-you-need-to-know-about-the-anti-covid-19-drug.html


Comments

Post a Comment

Popular posts from this blog

Stem Cell Therapy Patient Testimonial

By
 Stem Cell Therapy Patient Testimonial - GIOSTAR India Web: https://www.giostar.com/ Email: stemcells@giostar.com GIOSTAR Ahmedabad:  +91-7043008890 GIOSTAR Bangalore: +91-6366209990 GIOSTAR Chandigarh: +91-9501768105 #STEM #stemcells #Ahmedabad #Bangalore #chandigarh #mohali #therapy #testimonial #review #giostar #patientreview #patienttestimonial #giostarindia
Post a Comment
Read more

Stem Cell Therapy for Joints Pain

By
 Stem Cell Therapy for Joints Pain Stem cell therapy is a type of regenerative medicine that has shown promising results in treating joint pain. The goal of stem cell therapy is to promote the growth of new, healthy tissue to replace damaged tissue. Stem cells are the cells which have the ability to differentiate into various types of cells in the body. This means that they can become cells that are needed for repairing damaged tissue. When it comes to joint pain, stem cell therapy involves the use of mesenchymal stem cells (MSCs), which have the ability to differentiate into bone, cartilage, and other types of cells. These cells are often taken from the patient's own body, from adipose tissue (fat), and then processed and injected directly into the affected joint. Web: https://www.giostar.com/ Email: stemcells@giostar.com GIOSTAR Ahmedabad:  +91-7043008890 GIOSTAR Bangalore: +91-6366209990 GIOSTAR Chandigarh: +91-9501768105 #stemcell #antiaging #stemcelltherapy #nexentury #gl...
Post a Comment
Read more

Stem Cell Therapy for Knee Pain

By
  Stem Cell Therapy for Knee Pain Stem cell therapy is a non-invasive treatment that can help reduce inflammation, repair damaged tissue, and prevent knee replacement surgery. Stem cell injections are able to regenerate knee joints and keep patients out of the operating room. Studies suggest that side effects are minimal and temporary after the procedure. Stem cell therapy can be used to treat knee osteoarthritis, cartilage degeneration, and various acute conditions. Mayo Clinic offers a unique regenerative medicine approach for repairing knee cartilage using stem cells which can be completed in a single surgery. How Effective is Stem Cell Therapy for Knee Pain According to several studies, stem cell therapy is an effective and safe treatment for knee osteoarthritis that considerably reduces pain and improves the function of the knee. Stem cell therapy may delay or prevent knee replacement surgery and result in significant global health and economic benefit. While overall results a...
Post a Comment
Read more